	•		1
		1	
Please type a plus sign (+)	inside this	box →	+

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

C mplete if Known

_		_	Substitute for form 1449A/P	1
5	0		INFORMATION	١
n		2	STATEMENT	E

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Application Number 09/719,410

Filing Date December 12, 2000

First Named Inventor Burkhard Goke et al.

Group Art Unit /65 \$

Examiner Name Application P03986US2

U.S. PATENT DOCUMENTS									
Examiner Cite Initials' No.1	Cito	U.S. Paten	t Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant			
		Number	Kind Code ² (If known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			
									
			_						
		· · · · · · · · · · · · · · · · · · ·			- 				
				· · · · · · · · · · · · · · · · · · ·					
					 				
			 - -			. 			
1									
					<u> </u>				

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Do	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т¢
m	1		W0 98 08531 A		Eli Lilly and Company	1998-03-05	pgs. 23-24	
								\vdash
			· · · · · · · · · · · · · · · · · · ·					\vdash
								\Box
								\vdash

				_			, ,	
Examiner	111111	1 ~	$\Delta A I$	//	Date		/ /	_
Signature	ISK NOV	A- (VVIologue	\	Considered	- m I	17 /	05
Cigilatars	73090		11/000000000000000000000000000000000000			10/	<u> </u>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

Please type	a plus	sign (+)	inside	this	box	->	ابدا
		,				_	T .

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	ute for form 1449E	VPTO		Complete if Kn wn				
				Application Number	09/719,410			
INF	ORMATI	on di	SCLOSURE	Filing Date	December 12, 2000			
STATEMENT BY APPLICANT				First Named Inventor	Burkhard Goke et al.			
				Group Art Unit				
	(use as ma	ny sheets	as necessary)	Examiner Name				
heet	2	of	2	Attorney Docket Number	P03986US2			

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. RACHMAN J ET AL: "Near-normalisation of diurnal goucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM." DIABETOLOGIA, (1997 FEB) 40 (2) 205-11., XP002122529 CAVAGHAN M K ET AL: "Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance." JOURNAL OF CLINICAL INVESTIGATION, (1997 AUG 1) 100 (3) 530-7., XP002122530 the whole document BYRNE M M ET AL: "Glucagon - like peptide 1 improves the ability of the beta - cell to sense and respond to glucose in subjects with impaired glucose tolerance." DIABETES, (1998 AUG) 47 (8) 1259-65., XP002122530 the whole document

Examiner Date Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.